title: Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production.
abstract: The hepatitis C virus (HCV) p7 protein is critical for virus production and an attractive antiviral target. p7 is an ion channel when reconstituted in artificial lipid bilayers, but channel function has not been demonstrated in vivo and it is unknown whether p7 channel activity plays a critical role in virus production. To evaluate the contribution of p7 to organelle pH regulation and virus production, we incorporated a fluorescent pH sensor within native, intracellular vesicles in the presence or absence of p7 expression. p7 increased proton (H(+)) conductance in vesicles and was able to rapidly equilibrate H(+) gradients. This conductance was blocked by the viroporin inhibitors amantadine, rimantadine and hexamethylene amiloride. Fluorescence microscopy using pH indicators in live cells showed that both HCV infection and expression of p7 from replicon RNAs reduced the number of highly acidic (pH<5) vesicles and increased lysosomal pH from 4.5 to 6.0. These effects were not present in uninfected cells, sub-genomic replicon cells not expressing p7, or cells electroporated with viral RNA containing a channel-inactive p7 point mutation. The acidification inhibitor, bafilomycin A1, partially restored virus production to cells electroporated with viral RNA containing the channel inactive mutation, yet did not in cells containing p7-deleted RNA. Expression of influenza M2 protein also complemented the p7 mutant, confirming a requirement for H(+) channel activity in virus production. Accordingly, exposure to acid pH rendered intracellular HCV particles non-infectious, whereas the infectivity of extracellular virions was acid stable and unaffected by incubation at low pH, further demonstrating a key requirement for p7-induced loss of acidification. We conclude that p7 functions as a H(+) permeation pathway, acting to prevent acidification in otherwise acidic intracellular compartments. This loss of acidification is required for productive HCV infection, possibly through protecting nascent virus particles during an as yet uncharacterized maturation process.
authors.affiliation: Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
authors.forename: Ann L
authors.initials: AL
authors.lastname: Wozniak
authors.forename: Stephen
authors.initials: S
authors.lastname: Griffin
authors.forename: David
authors.initials: D
authors.lastname: Rowlands
authors.forename: Mark
authors.initials: M
authors.lastname: Harris
authors.forename: MinKyung
authors.initials: M
authors.lastname: Yi
authors.forename: Stanley M
authors.initials: SM
authors.lastname: Lemon
authors.forename: Steven A
authors.initials: SA
authors.lastname: Weinman
mesh_terms: D000547:Amantadine / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology; D015153:Blotting, Western; D018274:Electroporation; D016174:Hepacivirus / Q000502:physiology*; D006526:Hepatitis C / Q000378:metabolism* / Q000821:virology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007473:Ion Channels / Q000187:drug effects; D007668:Kidney / Q000166:cytology / Q000378:metabolism / Q000821:virology; D008051:Lipid Bilayers / Q000378:metabolism; D018942:Macrolides / Q000494:pharmacology; D009154:Mutation / Q000235:genetics; D011522:Protons; D012367:RNA, Viral / Q000235:genetics; D012299:Rimantadine / Q000494:pharmacology; D013347:Subcellular Fractions; D014158:Transcription, Genetic; D014764:Viral Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D014771:Virion / Q000502:physiology*; D053586:Virus Internalization / Q000187:drug effects; D014779:Virus Replication; D000086082:Viroporin Proteins
chemical_list: D000547:Amantadine; D000935:Antifungal Agents; D000998:Antiviral Agents; D007473:Ion Channels; D008051:Lipid Bilayers; D018942:Macrolides; D011522:Protons; D012367:RNA, Viral; D012299:Rimantadine; D014764:Viral Proteins; C088369:p7 protein, Hepatitis C virus; D000086082:Viroporin Proteins; C040929:bafilomycin A1
references.citation: J Biol Chem. 2008 Mar 28;283(13):8089-101
references.pmid: 18198177
references.citation: J Virol. 2007 Jan;81(2):629-38
references.pmid: 17079282
references.citation: J Virol. 2004 Jan;78(1):502-7
references.pmid: 14671130
references.citation: J Virol. 2009 Aug;83(16):7970-81
references.pmid: 19493992
references.citation: Hepatology. 2008 Dec;48(6):1779-90
references.pmid: 18828153
references.citation: J Neurochem. 2008 Dec;107(6):1709-21
references.pmid: 19014382
references.citation: Virology. 2002 Dec 20;304(2):197-210
references.pmid: 12504562
references.citation: J Biol Chem. 2006 Dec 1;281(48):37057-68
references.pmid: 17032656
references.citation: J Virol. 2005 Dec;79(24):15525-36
references.pmid: 16306623
references.citation: J Virol. 2001 Jun;75(12):5656-62
references.pmid: 11356973
references.citation: FEBS Lett. 2003 Sep 18;552(1):28-34
references.pmid: 12972148
references.citation: FEBS Lett. 2003 Sep 18;552(1):61-7
references.pmid: 12972153
references.citation: Proc Natl Acad Sci U S A. 2003 May 13;100(10):6104-8
references.pmid: 12719519
references.citation: J Virol. 2000 Oct;74(20):9498-506
references.pmid: 11000219
references.citation: J Viral Hepat. 2010 Nov;17(11):784-93
references.pmid: 20002299
references.citation: Am J Physiol. 1985 Mar;248(3 Pt 1):C372-8
references.pmid: 2579573
references.citation: J Cell Biol. 1996 May;133(4):733-47
references.pmid: 8666660
references.citation: PLoS Pathog. 2007 Jul;3(7):e103
references.pmid: 17658949
references.citation: J Biol Chem. 2006 Apr 7;281(14):8997-9000
references.pmid: 16407184
references.citation: Nat Protoc. 2006;1(5):2334-9
references.pmid: 17406476
references.citation: J Med Chem. 2006 Jan 26;49(2):648-55
references.pmid: 16420050
references.citation: J Virol. 2006 Feb;80(4):1734-41
references.pmid: 16439530
references.citation: Antiviral Res. 2006 Mar;69(3):129-41
references.pmid: 16413618
references.citation: J Virol. 2007 Aug;81(16):8374-83
references.pmid: 17537845
references.citation: J Virol. 2002 Feb;76(3):1391-9
references.pmid: 11773413
references.citation: J Virol. 2002 Apr;76(8):3720-30
references.pmid: 11907211
references.citation: Hepatology. 2008 Nov;48(5):1404-11
references.pmid: 18846541
references.citation: J Gen Virol. 2004 Feb;85(Pt 2):451-461
references.pmid: 14769903
references.citation: Microbes Infect. 2008 Jul;10(9):960-7
references.pmid: 18672082
references.citation: FEBS Lett. 2003 Jan 30;535(1-3):34-8
references.pmid: 12560074
references.citation: Curr Pharm Des. 2007;13(31):3231-5
references.pmid: 18045172
references.citation: Acta Microbiol Immunol Hung. 2003;50(4):433-42
references.pmid: 14750442
references.citation: Antiviral Res. 2007 Oct;76(1):48-58
references.pmid: 17574688
references.citation: Photochem Photobiol Sci. 2006 Jun;5(6):629-32
references.pmid: 16761092
references.citation: J Virol. 2009 Nov;83(22):11682-93
references.pmid: 19726506
references.citation: Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12712-6
references.pmid: 19590017
references.citation: FEBS Lett. 2004 Jan 16;557(1-3):99-103
references.pmid: 14741348
references.citation: Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11646-51
references.pmid: 14504405